To examine cultural aspects in social anxiety and social anxiety disorder (SAD), we reviewed the literature on the prevalence rates, expressions, and treatments of social anxiety/SAD as they relate to culture, race, and ethnicity. We further reviewed factors that contribute to the differences in soc
Why take social anxiety disorder seriously?
✍ Scribed by Jean-Pierre Lépine; Antoine Pélissolo
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 88 KB
- Volume
- 11
- Category
- Article
- ISSN
- 1091-4269
No coin nor oath required. For personal study only.
✦ Synopsis
Social anxiety disorder (social phobia) is a disabling psychiatric condition, characterized by a fear of negative evaluation by others. Epidemiological studies have shown a high prevalence of the condition in the general population; the disorder is more common in women than in men. Social anxiety disorder has a typical onset during adolescence and a chronic course; remission rarely occurs without therapeutic intervention. Comorbid psychiatric conditions such as depression and alcoholism commonly occur in patients with preexisting social anxiety disorder, and increase the burden of the condition. Two subtypes of social anxiety disorder have been identified: "nongeneralized" and "generalized"; the latter form causes greater disability and is more often associated with comorbidity.
The socioeconomic impact of social anxiety disorder on both sufferers and the community is considerable. For a person with social anxiety disorder, quality of life is greatly reduced; work, social, and personal relationships are all affected. Social anxiety disorder demands increased recognition, so that sufferers receive the treatment they need, in order to improve their quality of life through better social functioning.
📜 SIMILAR VOLUMES
Social anxiety disorder (social phobia) is a chronic disabling condition. As with many psychiatric disorders, the condition is likely to have several causes, including genetic and familial factors, early experiences, and cognitive mechanisms. This review will briefly examine the etiology of social a
## Abstract Tiagabine, a selective gamma‐aminobutyric acid (GABA) reuptake inhibitor was evaluated for the treatment of patients with social anxiety disorder (SAD). Adults with SAD received open‐label tiagabine 4–16 mg per day for 12 weeks. Intent‐to‐treat data are available for 54 patients with im